# Carl Bate

> Carl Bate is the British software engineer, technology executive and founder behind Evidium, a San Francisco company building computational models intended to make complex medical knowledge traceable and usable by machines. A programmer since childhood, Bate moved from software engineering at Guardian Royal Exchange through CTO and consulting leadership roles at Javelin Group, Capgemini, Atos Consulting and Arthur D. Little before founding Evidium in 2021. His work now centers on knowledge integrity, transparent reasoning and AI systems designed to support expert judgment.

- **Role:** Founder and CEO at Evidium
- **Organizations:** Evidium, Arthur D. Little, Atos Consulting, Capgemini, Javelin Group, AXA, BCS, The Chartered Institute for IT
- **Nationality:** British
- **Education:** Offered a place to study Artificial Intelligence; chose a software engineering role instead, The University of Edinburgh
- **Known for:** Founded Evidium and led the company through a $22 million Series A financing in 2025., Named inventor on multiple granted U.S. patents concerning computational evidence, patient-state determination and next-best-action systems., Served as CTO of Capgemini UK and on an executive board responsible for about 2,000 staff.

## Career timeline

- **1989-1998** — Worked at Guardian Royal Exchange, later part of AXA, beginning as a PL/1 and COBOL CICS software developer and progressing to Director of Software Engineering.
- **2000-2003** — Served as Chief Technology Officer at Javelin Group.
- **2003-2009** — Served as Chief Technology Officer at Capgemini UK, where he sat on an executive board responsible for about 2,000 staff.
- **2009-2014** — Worked at Atos Consulting, including as Managing Partner and head of CIO Advisory.
- **2015-2021** — Partner at Arthur D. Little; co-led its artificial intelligence and digital problem-solving work and led digital health globally.
- **2021-present** — Founder and CEO of Evidium in San Francisco.
- **2023** — Evidium launched publicly from stealth around its Referenced AI approach and announced a collaboration with Syntropy.
- **2025** — Evidium closed a $22 million Series A co-led by Health2047 and WGG Partners.

## Achievements

- Founded Evidium and led the company through a $22 million Series A financing in 2025.
- Named inventor on multiple granted U.S. patents concerning computational evidence, patient-state determination and next-best-action systems.
- Served as CTO of Capgemini UK and on an executive board responsible for about 2,000 staff.
- Co-founded and co-led Arthur D. Little’s Digital Problem Solving practice across London and New York.
- Co-developed and wrote about next-practice problem-solving approaches, including Pattern Breaking Pattern Matching and the VPEC-T framework.
- Elected a Fellow of the British Computer Society and previously chaired the BCS Futures Group.

## Latest updates

- **2026-05** — A further Evidium patent naming Bate and colleagues as inventors was granted for translating medical evidence into computational evidence and related applications.
- **2026-02** — Evidium received another U.S. grant in its computational-evidence patent family.
- **2026-01** — Multiple U.S. patents in Evidium’s computational-evidence and next-best-action portfolio were granted.
- **2025-11** — Evidium announced the close of a $22 million Series A co-led by Health2047 and WGG Partners, with participation from Interwoven Ventures and Mindset Ventures.
- **2025-10** — Evidium launched a predictive clinical disease-state, care and cost modeling solution for insurance and risk organizations.

## Links

- Website: https://www.evidium.com
- LinkedIn: https://www.linkedin.com/in/carl-bate
- Twitter/X: https://x.com/carlmwb
- YouTube: https://youtu.be/7ekTSr4BI4M

---

Profile page: https://yespress.io/carl-bate
Published by YesPress — https://yespress.io
Last updated: 2026-08-18